Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 13  |  Issue : 51  |  Page : 640-644

In Silico and In Vitro anticancer activity of isolated novel marker compound from chemically modified bioactive fraction from Curcuma longa (NCCL)


1 Department of Chemistry, Faculty of Science, Taibah University, Al-Madina Al-Munawwara, Kingdom of Saudi Arabia; Division of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India
2 Division of Pharmaceutics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India

Correspondence Address:
Arshi Naqvi
Department of Chemistry, Faculty of Science, Taibah University, P. O. Box. 344, Al-Madina Al-Munawwara, Kingdom of Saudi Arabia; Division of Pharmaceutics, CSIR-Central Drug Research Institute, B1/10.Jankipuram Extension, Sitapur Road, Lucknow-226 031, Uttar Pradesh

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_23_17

Rights and Permissions

Background: Turmeric (Curcuma longa) is reported to possess wide array of biological activities. Herbal Medicament (HM) is a standardized hexane-soluble fraction of C. longa and is well known for its neuroprotective effect. Objective: In this study, we attempted to synthesize a novel chemically modified bioactive fraction from HM (NCCL) along with isolation and characterization of a novel marker compound (I). Materials and Methods: NCCL was prepared from HM. The chemical structure of the marker compound isolated from NCCL was determined from 1D/2D nuclear magnetic resonance, mass spectroscopy, and Fourier transform infrared. The compound so isolated was subjected to in silico and in vitro screenings to test its inhibitory effect on estrogen receptors. Results: Molecular docking studies revealed that the binding poses of the compound I was energetically favorable. Among NCCL and compound I taken for in vitro studies, NCCL had exhibited good anti-cancer activity over compound I against MCF-7, MDA-MB-231, DU-145, and PC-3 cells. Conclusion: This is the first study about the synthesis of a chemically modified bioactive fraction which used a standardized extract since the preparation of the HM. It may be concluded that NCCL fraction having residual components induce more cell death than compound I alone. Thus, NCCL may be used as a potent therapeutic drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2387    
    Printed82    
    Emailed0    
    PDF Downloaded131    
    Comments [Add]    

Recommend this journal